Sfoglia per Autore
Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft.
2000-01-01 C. TARELLA; D. CARACCIOLO; P. CORRADINI; F. ZALLIO; M. LADETTO; A. CUTTICA; G. ROSSI; D. NOVERO; P. GAVAROTTI; A. PILERI
Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies.
2000-01-01 TROJAN A ;SCHULTZE JL ;WITZENS M ;VONDERHEIDE RH ;LADETTO M ;DONOVAN JW ;GRIBBEN JG
Immunoglobulin heavy-chain consensus probes for real-time PCR quantification of residual disease in acute lymphoblastic leukemia.
2000-01-01 J.W. DONOVAN; M. LADETTO; G. ZOU; D. NEUBERG; C. POOR; D. BOWERS; J.G. GRIBBEN
REAL TIME QUANTITATIVE PCR SHOWS THAT PERIPHERAK BLOOD STEM CELL (PBPC) HARVESTS ARE SIGNIFICANTILY LESS CONTAMINATED THAN BONE MARROW (BM) IN MULTIPLE MYELOMA PATIENTS (MM).
2000-01-01 Ladetto M; Omedè P; Sametti S; Donovan JW; Astolfi M; Giaccone L; Giaretta F; Volpato F; Bringhen S; Palumbo A; Bruno B; Pileri A; Gribben JG; Boccadoro M.
MULTIPLE MYELOMA: DIFFERENT PHENOTYPIC CHARACTERISTICS ARE SHOWN BY PLASMA CELLS FROM LEUKAPHERESIS AND BONE MARROW
2000-01-01 Omedè P; Giaretta F; Palumbo A; Ladetto M; Bruno B; Gilestro M; Sirica S; Rus C; Bringhen S; Triolo S; Giaccone L; Boccadoro M
Central nervous system relapse in a patient with mantle cell lymphoma in continuous clinical and molecular remission at six years since autografting.
2001-01-01 M. LADETTO; S. SAMETTI; M. ASTOLFI; P. CORRADINI; I. RICCA; D. DRANDI; A. PILERI; C. TARELLA
Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma.
2001-01-01 LADETTO M; ZALLIO F; VALLET S; RICCA I; CUTTICA A; CARACCIOLO D; CORRADINI P; ASTOLFI M; SAMETTI S; VOLPATO F; BONDESAN P; VITOLO U; M. BOCCADORO; PILERI A; GIANNI AM; TARELLA C.
MOLECULAR REMISSION IN A MULTIPLE MYELOMA PATIENT AFTER A NON MYELOABLATIVE ALLOGENEIC TRANSPLANT: PROOF OF PRINCIPLE
2001-01-01 Bruno B; Ladetto M; Astolfi M; Sametti S; Veneziano L; Aitoro G; Giaccone L; Palumbo A; Pileri A; Boccadoro M; Storb R
REAL TIME PCR IN MULTIPLE MYELOMA: QUANTITATIVE ANALYSIS OF TUMOR CONTAMINATION OF STEM CELL HARVESTS
2001-01-01 Ladetto M; Omedè P; Sametti S; Donovan JW; Drandi D; Giaccone L; Volpato F; Astolfi M; Giaretta F; Palumbo A; Bruno B; Pileri A; Gribben JG; Boccadoro M
A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients.
2001-01-01 M. LADETTO; SAMETTI S; DONOVAN JW; FERRERO D; ASTOLFI M; MITTERER M; RICCA I; DRANDI D; CORRADINI P; COSER P; PILERI A; GRIBBEN JG; TARELLA C.
High-dose mitoxantrone + melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: high tolerability with reversible cardiotoxicity.
2001-01-01 Tarella C; Zallio F; Caracciolo D; Cuttica A; Corradini P; Gavarotti P; Ladetto M; Podio V; Sargiotto A; Rossi G; Gianni AM; Pileri A
High-dose sequential (HDS) chemotherapy for high-risk non-Hodgkin's lymphoma: long-term analysis and future developments.
2001-01-01 TARELLA C; CUTTICA A; CARACCIOLO D; ZALLIO F; RICCA I; BERGUI L; GAVAROTTI P; MARINONE C; PAGANO M; ROSSI G; DE CRESCENZO A; SALOMONE A; LADETTO M; BOCCADORO M; PILERI A.
CYTOFLUORIMETRIC MONITORING OF MINIMAL RESIDUAL DISEASE CAN PREDICT CLINICAL REMISSION IN MULTIPLE MYELOMA PATIENTS UNDERGOING NON MYELOABLATIVE ALLOGENEIC TRANSPLANTATION
2002-01-01 Omedè P; Bruno B; Giaretta F; Ladetto M; Battaglio S; Ruggeri M; Di Bello Cristina; Morrone F; Aitoro G; Rotta M; Boccadoro M
High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO).
2002-01-01 LADETTO M; CORRADINI P; VALLET S; BENEDETTI F; VITOLO U; MARTELLI M; BRUGIATELLI M; COSER P; PERROTTI A; MAJOLINO I; FIORITONI G; MORANDI G; MUSSO M; ZAMBELLO R; CHISESI T; DI RENZO N; VIVALDI P; DE CRESCENZO A; GALLAMINI A; SALVI F; SANTINI G; BOCCOMINI C; SORIO M; ASTOLFI M; DRANDI D; PILERI A; TARELLA C
Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies.
2002-01-01 CORRADINI P; TARELLA C; OLIVIERI A; GIANNI AM; VOENA C; ZALLIO F; LADETTO M; FALDA M; LUCESOLE M; DODERO A; CICERI F; BENEDETTI F; RAMBALDI A; SAJEVA MR; TRESOLDI M; BORDIGNON C; BREGNI M
Qualitative and quantitative polymerase chain reaction detection of the residual myeloma cell contamination after positive selection of CD34+ cells with small- and large-scale Miltenyi cell sorting system.
2002-01-01 VOENA C; LOCATELLI G; CASTELLINO C; OMED P; M. LADETTO; FERRERO D; ZAPPONE E; PERFETTI V; BOCCADORO M; PILERI A; LUSSO P; VILLA C; MALNATI M; CORRADINI P
Real-time polymerase chain reaction in multiple myeloma: quantitative analysis of tumor contamination of stem cell harvests.
2002-01-01 Ladetto M; Omede P; Sametti S; Donovan JW; Astolfi M; Drandi D; Volpato F; Giaccone L; Giaretta F; Palumbo A; Bruno B; Pileri A; Gribben JG; Boccadoro M
Molecular monitoring of minimal residual disease after non-myeloablative allografting for multiple myeloma
2003-01-01 Bruno B; Ladetto M; Mordini N; Astolfi M; Rotta M; Cimolin L; Compagno M; Veneziano L; Aitoro G; Gallamini A ; Storb R; Boccadoro M
PCR-detectable non-neoplastic Bcl-2/IgH rearrangements are common in normal subjects and cancer patients at diagnosis, but rare in subjects treated with chemotherapy.
2003-01-01 Ladetto M; Drandi D; Volpato F; Astolfi M; Voena C; Compagno M; Novarino A; Pollio B; Addeo A; Ricca I; Falco P; Cavallo F; Vallet S; Corradini P; Pileri A; Tamponi G; Palumbo A; Bertetto O; Boccadoro M; Tarella C
Patients with high-risk aggressive lymphoma treated with frontline intensive chemotherapy and autografting: evidence of marked differences in outcome between patients with age-adjusted International Prognostic Index scores 2 and 3.
2003-01-01 CUTTICA A; ZALLIO F; LADETTO M; DI NICOLA M; CARACCIOLO D; MAGNI M; MARINONE C; DELL'AQUILA M; ROSACE M; PILERI A; BOCCADORO M; GIANNI AM; C. TARELLA
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft. | 2000 | C. TARELLA; D. CARACCIOLO; P. CORRADINI; F. ZALLIO; M. LADETTO; A. CUTTICA; G. ROSSI; D. NOVERO; P. GAVAROTTI; A. PILERI | |
| Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies. | 2000 | TROJAN A ;SCHULTZE JL ;WITZENS M ;VONDERHEIDE RH ;LADETTO M ;DONOVAN JW ;GRIBBEN JG | |
| Immunoglobulin heavy-chain consensus probes for real-time PCR quantification of residual disease in acute lymphoblastic leukemia. | 2000 | J.W. DONOVAN; M. LADETTO; G. ZOU; D. NEUBERG; C. POOR; D. BOWERS; J.G. GRIBBEN | |
| REAL TIME QUANTITATIVE PCR SHOWS THAT PERIPHERAK BLOOD STEM CELL (PBPC) HARVESTS ARE SIGNIFICANTILY LESS CONTAMINATED THAN BONE MARROW (BM) IN MULTIPLE MYELOMA PATIENTS (MM). | 2000 | Ladetto M; Omedè P; Sametti S; Donovan JW; Astolfi M; Giaccone L; Giaretta F; Volpato F; Bringhen S; Palumbo A; Bruno B; Pileri A; Gribben JG; Boccadoro M. | |
| MULTIPLE MYELOMA: DIFFERENT PHENOTYPIC CHARACTERISTICS ARE SHOWN BY PLASMA CELLS FROM LEUKAPHERESIS AND BONE MARROW | 2000 | Omedè P; Giaretta F; Palumbo A; Ladetto M; Bruno B; Gilestro M; Sirica S; Rus C; Bringhen S; Triolo S; Giaccone L; Boccadoro M | |
| Central nervous system relapse in a patient with mantle cell lymphoma in continuous clinical and molecular remission at six years since autografting. | 2001 | M. LADETTO; S. SAMETTI; M. ASTOLFI; P. CORRADINI; I. RICCA; D. DRANDI; A. PILERI; C. TARELLA | |
| Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma. | 2001 | LADETTO M; ZALLIO F; VALLET S; RICCA I; CUTTICA A; CARACCIOLO D; CORRADINI P; ASTOLFI M; SAMETTI S; VOLPATO F; BONDESAN P; VITOLO U; M. BOCCADORO; PILERI A; GIANNI AM; TARELLA C. | |
| MOLECULAR REMISSION IN A MULTIPLE MYELOMA PATIENT AFTER A NON MYELOABLATIVE ALLOGENEIC TRANSPLANT: PROOF OF PRINCIPLE | 2001 | Bruno B; Ladetto M; Astolfi M; Sametti S; Veneziano L; Aitoro G; Giaccone L; Palumbo A; Pileri A; Boccadoro M; Storb R | |
| REAL TIME PCR IN MULTIPLE MYELOMA: QUANTITATIVE ANALYSIS OF TUMOR CONTAMINATION OF STEM CELL HARVESTS | 2001 | Ladetto M; Omedè P; Sametti S; Donovan JW; Drandi D; Giaccone L; Volpato F; Astolfi M; Giaretta F; Palumbo A; Bruno B; Pileri A; Gribben JG; Boccadoro M | |
| A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients. | 2001 | M. LADETTO; SAMETTI S; DONOVAN JW; FERRERO D; ASTOLFI M; MITTERER M; RICCA I; DRANDI D; CORRADINI P; COSER P; PILERI A; GRIBBEN JG; TARELLA C. | |
| High-dose mitoxantrone + melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: high tolerability with reversible cardiotoxicity. | 2001 | Tarella C; Zallio F; Caracciolo D; Cuttica A; Corradini P; Gavarotti P; Ladetto M; Podio V; Sargiotto A; Rossi G; Gianni AM; Pileri A | |
| High-dose sequential (HDS) chemotherapy for high-risk non-Hodgkin's lymphoma: long-term analysis and future developments. | 2001 | TARELLA C; CUTTICA A; CARACCIOLO D; ZALLIO F; RICCA I; BERGUI L; GAVAROTTI P; MARINONE C; PAGANO M; ROSSI G; DE CRESCENZO A; SALOMONE A; LADETTO M; BOCCADORO M; PILERI A. | |
| CYTOFLUORIMETRIC MONITORING OF MINIMAL RESIDUAL DISEASE CAN PREDICT CLINICAL REMISSION IN MULTIPLE MYELOMA PATIENTS UNDERGOING NON MYELOABLATIVE ALLOGENEIC TRANSPLANTATION | 2002 | Omedè P; Bruno B; Giaretta F; Ladetto M; Battaglio S; Ruggeri M; Di Bello Cristina; Morrone F; Aitoro G; Rotta M; Boccadoro M | |
| High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). | 2002 | LADETTO M; CORRADINI P; VALLET S; BENEDETTI F; VITOLO U; MARTELLI M; BRUGIATELLI M; COSER P; PERROTTI A; MAJOLINO I; FIORITONI G; MORANDI G; MUSSO M; ZAMBELLO R; CHISESI T; DI RENZO N; VIVALDI P; DE CRESCENZO A; GALLAMINI A; SALVI F; SANTINI G; BOCCOMINI C; SORIO M; ASTOLFI M; DRANDI D; PILERI A; TARELLA C | |
| Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. | 2002 | CORRADINI P; TARELLA C; OLIVIERI A; GIANNI AM; VOENA C; ZALLIO F; LADETTO M; FALDA M; LUCESOLE M; DODERO A; CICERI F; BENEDETTI F; RAMBALDI A; SAJEVA MR; TRESOLDI M; BORDIGNON C; BREGNI M | |
| Qualitative and quantitative polymerase chain reaction detection of the residual myeloma cell contamination after positive selection of CD34+ cells with small- and large-scale Miltenyi cell sorting system. | 2002 | VOENA C; LOCATELLI G; CASTELLINO C; OMED P; M. LADETTO; FERRERO D; ZAPPONE E; PERFETTI V; BOCCADORO M; PILERI A; LUSSO P; VILLA C; MALNATI M; CORRADINI P | |
| Real-time polymerase chain reaction in multiple myeloma: quantitative analysis of tumor contamination of stem cell harvests. | 2002 | Ladetto M; Omede P; Sametti S; Donovan JW; Astolfi M; Drandi D; Volpato F; Giaccone L; Giaretta F; Palumbo A; Bruno B; Pileri A; Gribben JG; Boccadoro M | |
| Molecular monitoring of minimal residual disease after non-myeloablative allografting for multiple myeloma | 2003 | Bruno B; Ladetto M; Mordini N; Astolfi M; Rotta M; Cimolin L; Compagno M; Veneziano L; Aitoro G; Gallamini A ; Storb R; Boccadoro M | |
| PCR-detectable non-neoplastic Bcl-2/IgH rearrangements are common in normal subjects and cancer patients at diagnosis, but rare in subjects treated with chemotherapy. | 2003 | Ladetto M; Drandi D; Volpato F; Astolfi M; Voena C; Compagno M; Novarino A; Pollio B; Addeo A; Ricca I; Falco P; Cavallo F; Vallet S; Corradini P; Pileri A; Tamponi G; Palumbo A; Bertetto O; Boccadoro M; Tarella C | |
| Patients with high-risk aggressive lymphoma treated with frontline intensive chemotherapy and autografting: evidence of marked differences in outcome between patients with age-adjusted International Prognostic Index scores 2 and 3. | 2003 | CUTTICA A; ZALLIO F; LADETTO M; DI NICOLA M; CARACCIOLO D; MAGNI M; MARINONE C; DELL'AQUILA M; ROSACE M; PILERI A; BOCCADORO M; GIANNI AM; C. TARELLA |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile